EDIT insider buying and SEC filings, explained
Editas Medicine, Inc. · CIK 1650664
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$107K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 3, 2026 | Planned (10b5-1) | Amy Parison (CFO) sold 453 shares at $3.04 ($1K), marked as a 10b5-1 plan trade. Holdings down 3% to 13,839 shares. | SEC filing Filed Sep 4, 2026 |
| Sep 3, 2026 | Planned (10b5-1) | Linda Burkly (EVP, Chief Scientific Officer) sold 709 shares at about $3.04 ($2K), marked as a 10b5-1 plan trade. Holdings down 1% to 61,660 shares. | SEC filing Filed Sep 4, 2026 |
| Sep 3, 2026 | Planned (10b5-1) | Gilmore Neil O'Neill (CEO and Director) sold 5,124 shares at about $3.04 ($16K), marked as a 10b5-1 plan trade. Holdings down 2% to 243,189 shares. | SEC filing Filed Sep 4, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Amy Parison (CFO) sold 678 shares at $2.58 ($2K), marked as a 10b5-1 plan trade. Holdings down 5% to 14,292 shares. | SEC filing Filed Aug 5, 2026 |
| Jul 28, 2026 | Planned (10b5-1) | Linda Burkly (EVP, Chief Scientific Officer) sold 4,928 shares at $2.67 ($13K), marked as a 10b5-1 plan trade. Holdings down 7% to 62,369 shares. | SEC filing Filed Jul 29, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Amy Parison (CFO) sold 464 shares at about $2.70 ($1K), marked as a 10b5-1 plan trade. Holdings down 3% to 14,970 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Gilmore Neil O'Neill (CEO and Director) sold 15,380 shares at about $2.70 ($42K), marked as a 10b5-1 plan trade. Holdings down 6% to 248,313 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Linda Burkly (EVP, Chief Scientific Officer) sold 731 shares at about $2.70 ($2K), marked as a 10b5-1 plan trade. Holdings down 1% to 67,297 shares. | SEC filing Filed Jun 5, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Gilmore Neil O'Neill (CEO and Director) sold 5,394 shares at about $2.02 ($11K), marked as a 10b5-1 plan trade. Holdings down 2% to 263,693 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Amy Parison (CFO) sold 474 shares at about $2.02 ($957), marked as a 10b5-1 plan trade. Holdings down 3% to 15,434 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Linda Burkly (EVP, Chief Scientific Officer) sold 749 shares at about $2.02 ($2K), marked as a 10b5-1 plan trade. Holdings down 1% to 68,028 shares. | SEC filing Filed Mar 4, 2026 |
| Dec 3, 2025 | Planned (10b5-1) | Linda Burkly (EVP, Chief Scientific Officer) sold 713 shares at $2.15 ($2K), marked as a 10b5-1 plan trade. Holdings down 1% to 68,777 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Gilmore Neil O'Neill (CEO and Director) sold 5,603 shares at $2.15 ($12K), marked as a 10b5-1 plan trade. Holdings down 2% to 269,087 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Amy Parison (CFO) sold 461 shares at $2.15 ($991), marked as a 10b5-1 plan trade. Holdings down 3% to 15,908 shares. | SEC filing Filed Dec 4, 2025 |
10 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow EDIT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.